表紙
市場調查報告書

神經退化性疾病治療藥物市場的成長機會:2024年前預測

Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market, Forecast to 2024

出版商 Frost & Sullivan 商品編碼 910115
出版日期 內容資訊 英文 89 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
神經退化性疾病治療藥物市場的成長機會:2024年前預測 Growth Opportunities in the Neurodegenerative Disorder Therapeutics Market, Forecast to 2024
出版日期: 2019年08月27日內容資訊: 英文 89 Pages
簡介

本報告研究神經退化性疾病治療藥物市場,除了量化市場之外、並提供未來產品及其可能產出相關收益之詳細資訊,分析各種技術進步、區域動向、阿茲海默症及帕金森氏症合作機會可能性、競爭策略和各企業策略、成長機會等情報。

績效儀錶板

市場概要和動態

  • 範圍和部門
  • 課題規模:阿茲海默症
  • 課題規模:帕金森氏症
  • 市場成長推動和阻礙因素
  • 阿茲海默症的研發生產力
  • 帕金森氏症的研發生產力
  • 對監管和定價政策的影響
  • 全球創新展望
  • 治療工作流程

預測和趨勢:整體神經退化性疾病治療藥物市場

  • 市場工程測量
  • 調查手法
  • 預測假設

阿茲海默症部門分析

  • 疾病診斷和管理概要
  • 市場工程測量
  • 收益預測
  • 可尋址的機會:藥物治療
  • 收益預測討論
  • 競爭情勢
  • 臨床PIPELINE概要
  • 高潛力PIPELINE產品

帕金森氏症部門分析

  • 疾病診斷和管理概要
  • 市場工程測量
  • 收益預測討論
  • 可尋址的機會:藥物治療
  • 收益預測討論
  • 競爭情勢
  • 臨床PIPELINE概要
  • 高潛力PIPELINE產品

競爭情勢:整體神經退化性疾病治療藥物市場

  • 競爭環境
  • 合作評估
  • 供應商生態系統
  • 矚目企業

願景情勢

  • 從宏觀至微觀的願景
  • 領域變化:數據整合的應用
  • 可尋址市場機會:數位解決方案
  • 數位治療的醫療費用償付情勢
  • 案例研討:新藥發現數位化 - BenevolentAI
  • 案例研討:臨床篩選數位化
  • 案例研討:臨床數位化
  • 案例研討:治療數位化
  • 案例研討:治療數位化 - Dthera Sciences
  • 案例研討:數位化實現個人化治療

成長機會

  • 5大主要成長機會
  • 成長機會1 - 數位生物標記
  • 成長機會2 - 微生物組療法
  • 成長機會3 - 細胞和基因療法
  • 成長機會4 - 藥物傳輸
  • 成長機會5 - 藥物重新定位

結論

附錄

目錄
Product Code: MECB-52

Digital Solutions will Spark Integrated Development Approaches and Successful Adjunctive Therapies for Disease Modification

As one lives longer, one needs to increasingly battle age-related disorders. Neurodegenerative disorders are the most worrisome, because they impact millions of people around the world and lack any curative therapy. While companies continue their search, they are also battling declining revenues from marketed products used to manage symptoms. Heavy genericization, followed by price erosion, reliance on patient-reported data for diagnosis and measuring outcomes, and elusive R&D success, has put unprecedented pressure on pharma companies and prompted several to shed their assets mid-way.

This research service, in addition to quantifying the market, provides details of future products and the expected revenue generation from them. While the therapy market is marred by high rates of pipeline attrition, there are several parallel areas of growth. For instance, the study covers regenerative medicine, which has grown by leaps and bounds and offers the promise of curative therapies. The study also dives deep into different technological advancements, geographical trends, and potential partnership opportunities for Alzheimer's and Parkinson's diseases. The study covers opportunities in prevention facilitated by digital solutions integration, in conjunction with an understanding of disease diagnosis and progression, expedited drug development, and, most importantly, delivery of the required outcome to the patient.

The study captures the competitive landscape and the different strategies employed by companies to stay ahead of the curve, and identifies the game-changing companies leading innovation from the front. Acknowledging the high cost of failure, the study investigates the need and growing acceptance of open innovation to curate data, ask better questions, extract meaningful insights, and create more accurate and predictable solutions. In addition to collaboration with peers, companies will seek partnership with digital partners. Given the growing availability of data, technologies and tools, and research expertise there are several companies seeking clinically validated solutions, which have been profiled in the study. The study lays down strategic imperatives for companies to recalibrate their business models based on collaboration and be future ready.

Information is also provided on some of the leading M&A activities impacting the market, as well as unconventional collaboration agreements laying the foundation for propelling innovations toward licensure and delivery. Furthermore, present and future market trends such as regulatory support, focus on wellness, and value chain convergence, which would shape the market, are discussed.

Key Issues Addressed:

  • What is the total market size and how is the growth projected for global neurodegenerative therapeutics? Which are the largest growth segments to be pursued?
  • How are the various regions around the globe positioned to monetize market opportunities? What are the key regional barriers to entry?
  • What are the new risk mitigation strategies and alternative big bets to circumvent R&D challenges? Which are the lucrative partnership models for the long term?
  • What are the market-defining macro trends mandating the need to deploy new digital therapeutic solutions to enable centric care in a variety of settings?
  • What are the implications of emerging technologies and digital transformation on the overall market?
  • Which are the key game-changing companies in the segment and how are they riding the growth curve?

Table of Contents

Executive Dashboard

  • Purpose of the Study
  • 5-step Process to Transformational Growth
  • Key Findings
  • Key Questions this Study will Answer
  • Market Engineering Measurements
  • Big Market Themes
  • Strategic Imperatives for Success and Growth

Market Overview and Dynamics

  • Scope and Segmentation
  • Scale of the Challenge-Alzheimer's
  • Scale of the Challenge-Parkinson's
  • Market Drivers and Restraints
  • R&D Productivity in Alzheimer's Disease
  • R&D Productivity in Parkinson's Disease
  • Funding Set to Catapult Pharma and Digital Solutions
  • Impact of Regulatory and Pricing Policies
  • Global Innovation Outlook
  • Treatment Workflow

Forecast and Trends-Total Neurodegenerative Disorder Therapeutics Market

  • Market Engineering Measurements
  • Methodology
  • Forecast Assumptions

Alzheimer's Disease Segment Analysis

  • Snapshot of Disease Diagnosis and Management
  • Market Engineering Measurements
  • Revenue Forecast
  • Addressable Opportunity-Pharmacological Therapies
  • Revenue Forecast Discussion
  • Competitive Landscape
  • Clinical Pipeline Overview
  • High-potential Pipeline Products

Parkinson's Disease Segment Analysis

  • Snapshot of Disease Diagnosis and Management
  • Market Engineering Measurements
  • Revenue Forecast Discussion
  • Addressable Opportunity-Pharmacological Therapies
  • Revenue Forecast Discussion
  • Competitive Landscape
  • Clinical Pipeline Overview
  • High-potential Pipeline Products

Competitive Landscape-Total Neurodegenerative Disorder Therapeutics Market

  • Competitive Environment
  • Collaboration Assessment
  • Collaboration Assessment (continued)
  • Collaboration Assessment (continued)
  • Vendor Ecosystem
  • Key Companies to Watch
  • Key Companies to Watch (continued)

Visioning Scenarios

  • Macro-to-Micro Visioning
  • Change on the Horizon-Applications for Digital Integration
  • Addressable Market Opportunity-Digital Solutions
  • Reimbursement Landscape for Digital Therapies
  • Case Study-Digitization of Drug Discovery: BenevolentAI
  • Case Study-Digitization of Screening for Clinical Trial
  • Case Study-Digitization of Clinical Trial: µMotif
  • Case Study-Digitization of Therapy
  • Case Study-Digitization of Therapy: Dthera Sciences
  • Case Study-Digitization-enabling Personalized Therapy

Growth Opportunities

  • 5 Major Growth Opportunities
  • Growth Opportunity 1-Digital Biomarkers
  • Definition and Applications of Digital Biomarkers
  • Overview of Relevant Digital Biomarkers
  • Growth Opportunity 2-Microbiome Therapeutics
  • Companies at the Forefront of Research
  • Growth Opportunity 3-Cell and Gene Therapy
  • Regenerative Medicine Clinical Trials Overview
  • Growth Opportunity 4-Drug Delivery
  • Collaborating to Bring Innovative Drug-Device Combination
  • Growth Opportunity 5-Drug Repurposing
  • Overview of Drug Repurposing Trials
  • Deficiencies in the Treatment Paradigm

The Last Word

  • Top 3 Predictions for the Market
  • Legal Disclaimer

Appendix

  • Statistics on Alzheimer's Disease
  • Statistics on Parkinson's Disease
  • List of Exhibits
  • List of Exhibits (continued)
  • List of Exhibits (continued)
Back to Top